Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNF alpha regulation and proliferation of hematopoietic progenitor cells


Por: Rio, P, Agirre, X, Garate, L, Banos, R, Alvarez, L, San Jose-Eneriz, E, Badell, I, Casado, JA, Garin, M, Prosper, F, Bueren, JA

Publicada: 29 mar 2012
Resumen:
Fanconi anemia (FA) is an inherited genetic disorder associated with BM failure and cancer predisposition. In the present study, we sought to elucidate the role of microRNAs (miRNAs) in the hematopoietic defects observed in FA patients. Initial studies showed that 3 miRNAs, hsa-miR-133a, hsa-miR-135b, and hsa-miR181c, were significantly down-regulated in lymphoblastoid cell lines and fresh peripheral blood cells from FA patients. In vitro studies with cells expressing the luciferase reporter fused to the TNF alpha 3'-untranslated region confirmed in silico predictions suggesting an interaction between hsa-miR-181c and TNF alpha mRNA. These observations were consistent with the down-regulated expression of TNF alpha mediated by hsa-miR-181c in cells from healthy donors and cells from FA patients. Because of the relevance of TNF alpha in the hematopoietic defects of FA patients, in the present study, we transfected BM cells from FA patients with hsa-miR-181c to evaluate the impact of this miRNA on their clonogenic potential. hsa-miR-181c markedly increased the number and size of the myeloid and erythroid colonies generated by BM cells from FA patients. Our results offer new clues toward understanding the biologic basis of BM failure in FA patients and open new possibilities for the treatment of the hematologic dysfunction in FA patients based on miRNA regulation. (Blood. 2012;119(13):3042-3049)

Filiaciones:
Rio, P:
 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain

Agirre, X:
 Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain

 Univ Navarra Clin, Dept Hematol, Pamplona, Spain

Garate, L:
 Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain

 Univ Navarra Clin, Dept Hematol, Pamplona, Spain

Banos, R:
 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain

Alvarez, L:
 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain

San Jose-Eneriz, E:
 Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain

 Univ Navarra Clin, Dept Hematol, Pamplona, Spain

Badell, I:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Casado, JA:
 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain

Garin, M:
 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain

Prosper, F:
 Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain

 Univ Navarra Clin, Dept Hematol, Pamplona, Spain

Bueren, JA:
 CIEMAT CIBERER, Ctr Invest Energet Medioambientales & Tecnol, Hematopoiesis & Gene Therapy Div, Madrid 28040, Spain

 Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain
ISSN: 00064971





BLOOD
Editorial
AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 119 Número: 13
Páginas: 3042-3049
WOS Id: 000302141200018
ID de PubMed: 22310912

MÉTRICAS